ESPERION: REVOLUTIONIZING THE PHARMA INDUSTRY $
Post# of 6
(Total Views: 93)
Posted On: 07/15/2024 9:03:07 AM
ESPERION: REVOLUTIONIZING THE PHARMA INDUSTRY
$ESPR
Excited to share an article about Esperion Therapeutics Inc. (NASDAQ: ESPR), a pharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C).
Esperion has introduced the first oral non-statin LDL-C lowering therapy in 20 years, targeting a large market with high unmet needs. The company has received approval and an expanded label from the FDA for two drugs. Additionally, it has reported a 467% increase in total revenues for Q1 FY24 and a 54% increase for FY23, showing the potential for exponential growth. This makes it an intriguing opportunity to watch.
Read on to know more:
https://www.aviseanalytics.com/esperion-revol...-industry/
$ESPR
Excited to share an article about Esperion Therapeutics Inc. (NASDAQ: ESPR), a pharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients with elevated low-density lipoprotein cholesterol (LDL-C).
Esperion has introduced the first oral non-statin LDL-C lowering therapy in 20 years, targeting a large market with high unmet needs. The company has received approval and an expanded label from the FDA for two drugs. Additionally, it has reported a 467% increase in total revenues for Q1 FY24 and a 54% increase for FY23, showing the potential for exponential growth. This makes it an intriguing opportunity to watch.
Read on to know more:
https://www.aviseanalytics.com/esperion-revol...-industry/
(0)
(0)Esperion Therapeutics Inc. (ESPR) Stock Research Links
Scroll down for more posts ▼